BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31364339)

  • 1. Possible clinical indications of ceftobiprole.
    Barberán J
    Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):29-33. PubMed ID: 31364339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftobiprole for the treatment of pneumonia: a European perspective.
    Liapikou A; Cillóniz C; Torres A
    Drug Des Devel Ther; 2015; 9():4565-72. PubMed ID: 26316697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftobiprole: drug evaluation and place in therapy.
    Giacobbe DR; De Rosa FG; Del Bono V; Grossi PA; Pea F; Petrosillo N; Rossolini GM; Tascini C; Tumbarello M; Viale P; Bassetti M
    Expert Rev Anti Infect Ther; 2019 Sep; 17(9):689-698. PubMed ID: 31553250
    [No Abstract]   [Full Text] [Related]  

  • 4. Ceftobiprole for the treatment of pneumonia.
    Cillóniz C; Dominedò C; Garcia-Vidal C; Torres A
    Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):17-23. PubMed ID: 31364337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.
    Syed YY
    Drugs; 2014 Sep; 74(13):1523-42. PubMed ID: 25117196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
    Horn KS; Danziger LH; Rodvold KA; Glowacki RC
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):463-472. PubMed ID: 28264613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antibiotic therapy in elderly patients].
    Bellmann-Weiler R; Weiss G
    Dtsch Med Wochenschr; 2008 Feb; 133(8):350-3. PubMed ID: 18270915
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.
    Lagacé-Wiens PR; Rubinstein E
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):789-99. PubMed ID: 23590397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
    Stein GE; Wells EM
    Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.
    Scheeren TW
    Future Microbiol; 2015; 10(12):1913-28. PubMed ID: 26573022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients.
    Bosheva M; Gujabidze R; Károly É; Nemeth A; Saulay M; Smart JI; Hamed KA
    Pediatr Infect Dis J; 2021 Jun; 40(6):e222-e229. PubMed ID: 33480665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefoperazone: an analysis of results in the pediatric population from a post-marketing surveillance study in hospitalized patients. The Cefoperazone Collaborative Post-marketing Surveillance Study Group.
    Indian J Pediatr; 1998; 65(1):89-98. PubMed ID: 10771951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complicated skin and soft tissue infection.
    Dryden MS
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 3():iii35-44. PubMed ID: 20876627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftaroline fosamil (Teflaro) - a new IV cephalosporin.
    Med Lett Drugs Ther; 2011 Jan; 53(1356):5-6. PubMed ID: 21252841
    [No Abstract]   [Full Text] [Related]  

  • 15. [Ceftaroline fosamil, a broad spectrum cephalosporin antibiotic for the treatment of community-acquired pneumonia and complicated skin and skin structure infections].
    Nikitin AV
    Antibiot Khimioter; 2011; 56(7-8):47-9. PubMed ID: 22359871
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic profile of ceftobiprole.
    Lodise TP; Patel N; Renaud-Mutart A; Gorodecky E; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):96-102. PubMed ID: 18384996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations.
    Torres A; Mouton JW; Pea F
    Clin Pharmacokinet; 2016 Dec; 55(12):1507-1520. PubMed ID: 27272266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of a possible signal of increased mortality associated with cefepime use.
    Kim PW; Wu YT; Cooper C; Rochester G; Valappil T; Wang Y; Kornegay C; Nambiar S
    Clin Infect Dis; 2010 Aug; 51(4):381-9. PubMed ID: 20624065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Uncertainties in the therapy of infectious diseases].
    Heimann D
    Dtsch Med Wochenschr; 2014 Nov; 139 Suppl 3():S82. PubMed ID: 25429535
    [No Abstract]   [Full Text] [Related]  

  • 20. Ceftobiprole medocaril for the treatment of community-acquired pneumonia.
    Falcó V; Burgos J; Almirante B
    Expert Opin Pharmacother; 2018 Sep; 19(13):1503-1509. PubMed ID: 30198789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.